E3652
Epoxomicin
≥95% (HPLC), solid
동의어(들):
N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
CAS 번호:
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
제품 이름
Epoxomicin, ≥95% (HPLC), solid
InChI
1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
SMILES string
CC[C@H](C)[C@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
InChI key
DOGIDQKFVLKMLQ-JTHVHQAWSA-N
assay
≥95% (HPLC)
form
solid
storage temp.
−20°C
Quality Level
Application
Epoxomicin has been used:
- as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cells
- as a proteasome inhibitor in mammary epithelial MCF-10A cells
- as a proteasome inhibitor in chymotryptic assay in cardiomyocytes
Biochem/physiol Actions
Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent.
Epoxomicin, a natural product isolated from Actinomyces sp., is a cell-permeable, potent, selective and irreversible proteasome inhibitor.
General description
Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketone derived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated from Actinomyces sp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng L, et al.
Proceedings of the National Academy of Sciences of the USA, 96(18), 10403-10408 (1999)
Kyung Bo Kim et al.
Natural product reports, 30(5), 600-604 (2013-04-12)
The initial enthusiasm following the discovery of a pharmacologically active natural product is often fleeting due to the poor prospects for its ultimate clinical application. Despite this, the ever-changing landscape of modern biology has a constant need for molecular probes
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses
Schwarz K, et al.
Journal of Immunology, 164(12), 6147-6157 (2000)
Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology
Sin N, et al.
Bioorganic & medicinal chemistry letters, 9(15), 2283-2288 (1999)
Chymase uptake by cardiomyocytes results in myosin degradation in cardiac volume overload
Powell PC, et al.
Heliyon, 5(4), e01397-e01397 (2019)
관련 콘텐츠
Datasheet
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.